Fluorescein angiography of recurrent retinopathy of prematurity after initial intravitreous bevacizumab treatment

Arch Ophthalmol. 2010 Aug;128(8):1080-1. doi: 10.1001/archophthalmol.2010.145.
No abstract available

Publication types

  • Case Reports
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Angiogenesis Inhibitors / administration & dosage*
  • Antibodies, Monoclonal / administration & dosage*
  • Antibodies, Monoclonal, Humanized
  • Bevacizumab
  • Fluorescein Angiography*
  • Gestational Age
  • Humans
  • Infant, Extremely Low Birth Weight
  • Infant, Newborn
  • Injections
  • Laser Coagulation
  • Male
  • Recurrence
  • Retinopathy of Prematurity / diagnosis*
  • Retinopathy of Prematurity / etiology*
  • Retinopathy of Prematurity / surgery
  • Vascular Endothelial Growth Factor A / antagonists & inhibitors*
  • Vitreous Body

Substances

  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Vascular Endothelial Growth Factor A
  • Bevacizumab